title: Influence of azimilide on CYP2C19-mediated metabolism.
abstract: The purpose of this study was to assess the influence of multiple-dose oral administration of azimilide dihydrochloride on CYP2C19-mediated metabolism. A two-period, randomized crossover study was conducted in 40 healthy male subjects who were phenotyped as extensive CYP2C19 metabolizers. Oral doses of placebo or 125 mg of azimilide dihydrochloride were administered every 12 hours for 3 days, followed by every 24 hours for 5 days; 20 mg omeprazole was coadministered on Day 8. Blood or plasma samples were obtained over 24 hours and analyzed for azimilide or omeprazole/5-hydroxyomeprazole using high-performance liquid chromatography with tandem mass spectrometry. Data were analyzed using "noncompartmental" analysis. Azimilide blood concentrations observed in this study were similar to those previously observed at steady state in patients. Based on AUC(m)/AUC(p) for omeprazole, azimilide does not significantly inhibit CYP2C19-mediated metabolism (90% confidence interval [CI] = 104%-111%). For 5-hydroxyomeprazole, no significant changes in pharmacokinetics were observed. For omeprazole, a statistically significant decrease ( approximately 12%) was observed for AUC. However, this change was small and is not expected to be clinically important since the CI was contained within those used to establish bioequivalence. These results indicate that azimilide does not inhibit CYP2C19-mediated metabolism. Since this isozyme had the lowest in vitro IC(50) values for the cytochrome P450s most commonly involved with the metabolism of drugs (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4), azimilide-related drug interactions mediated via these isozymes are not anticipated.
authors.affiliation: Procter & Gamble Pharmaceuticals, Mason, OH 45040-9462, USA.
authors.forename: Mohamed
authors.initials: M
authors.lastname: El Mouelhi
authors.forename: Dan J
authors.initials: DJ
authors.lastname: Worley
authors.forename: Barbara
authors.initials: B
authors.lastname: Kuzmak
authors.forename: Anthony J
authors.initials: AJ
authors.lastname: Destefano
authors.forename: Gary A
authors.initials: GA
authors.lastname: Thompson
mesh_terms: D000328:Adult; D000889:Anti-Arrhythmia Agents / Q000097:blood / Q000493:pharmacokinetics*; D019540:Area Under Curve; D001189:Aryl Hydrocarbon Hydroxylases / Q000378:metabolism*; D002121:Calcium Channel Blockers / Q000097:blood / Q000493:pharmacokinetics*; D018592:Cross-Over Studies; D065731:Cytochrome P-450 CYP2C19; D004311:Double-Blind Method; D004791:Enzyme Inhibitors / Q000378:metabolism; D006801:Humans; D006827:Hydantoins; D007093:Imidazoles / Q000097:blood / Q000493:pharmacokinetics*; D048289:Imidazolidines; D008297:Male; D008875:Middle Aged; D006899:Mixed Function Oxygenases / Q000378:metabolism*; D009853:Omeprazole / Q000378:metabolism; D010879:Piperazines / Q000097:blood / Q000493:pharmacokinetics*
chemical_list: D000889:Anti-Arrhythmia Agents; D002121:Calcium Channel Blockers; D004791:Enzyme Inhibitors; D006827:Hydantoins; D007093:Imidazoles; D048289:Imidazolidines; D010879:Piperazines; C086123:azimilide; D006899:Mixed Function Oxygenases; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D009853:Omeprazole